Medicus Pharma (NASDAQ:MDCX) Upgraded by D Boral Capital to “Strong-Buy” Rating

Medicus Pharma (NASDAQ:MDCX) was upgraded by stock analysts at D Boral Capital to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

A number of other equities research analysts have also recently commented on the company. D. Boral Capital began coverage on Medicus Pharma in a research report on Monday. They set a “buy” rating and a $14.00 target price on the stock. Brookline Capital Management upgraded Medicus Pharma to a “strong-buy” rating in a research report on Monday, December 23rd. Finally, Maxim Group initiated coverage on shares of Medicus Pharma in a research note on Tuesday, December 17th. They set a “buy” rating and a $10.00 target price on the stock.

Medicus Pharma Stock Up 0.8 %

MDCX stock opened at $3.61 on Monday. The stock has a 50 day moving average of $3.46. Medicus Pharma has a 52 week low of $1.80 and a 52 week high of $6.00.

Medicus Pharma (NASDAQ:MDCX) last issued its earnings results on Friday, March 28th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.14. As a group, equities research analysts forecast that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC purchased a new stake in Medicus Pharma Ltd. (NASDAQ:MDCX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma accounts for approximately 1.3% of Interchange Capital Partners LLC’s holdings, making the stock its 15th largest holding. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma as of its most recent SEC filing.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.